India's Central Drugs Standard Control Organisation (CDSCO) says Pfizer officials failed to turn up to meetings after the company's application was made in early December

The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) on Tuesday recommended Bharat Biotech's intranasal vaccine for conducting phase 1 clinical trials for the coronavirus

Company shall be liable for all adversities as per CDSCO/Drugs and Cosmetics Act/DCGI policy/approval, says government's purchase order with vaccine makers

Pfizer is yet to submit additional data sought by India authorities regarding its COVID-19 vaccine for granting emergency use approval to it; the company has missed last three SEC meetings too

Bharat Biotech revealed that one of the participants for Phase III trials passed away on December 21, 2020, and the death was reported to the People's College of Medical Sciences and Research Centre by the son of the deceased

COVID-19 vaccination drive: This development comes after the government said that the vaccine would be rolled out 10 days after the date of approval for emergency use

This daunting challenge is not only for India but also for all the governments across the globe as they start inoculating their populations to tackle the pandemic, noted Dr Soumya Swaminathan, Chief Scientist of WHO

Bharat Biotech's Chairman and Managing Director Dr. Krishna Ella, in a press conference on Monday, January 5, clarified that its vaccine is safe and the company is conducting trials in over 12 countries besides India

Cadila Healthcare share touched an intraday high of Rs 492.95, rising 3.02% against previous close of Rs 478.50 on BSE

The phase-2 trials of Zydus Cadila's coronavirus vaccine had been conducted in around 1,000 healthy adults

The ICMR head emphasised that the scientists at ICMR have been successfully able to culture the UK strain and the efficacy of Covaxin against it will be further tested in days to come

PM Modi thanked doctors, medical staff, police personnel, sanitation workers and all corona warriors for their hard work during the coronavirus outbreak

COVID-19 vaccine in India: It would make every Indian proud that the two vaccines that have been given emergency use approval are made in India! This shows the eagerness of our scientific community to fulfil the dream of an Aatmanirbhar Bharat, said PM Modi

COVID-19 vaccines in India: Oxford-AstraZeneca's coronavirus vaccine Covishield and Bharat Biotech's COVID vaccine Covaxin will be India's first vaccines

Coronavirus vaccine trials: Bharat Biotech said that it is steadily moving towards its goal of 26,000 volunteers. Phase 3 of human clinical trials for Covaxin began in mid-November

The SEC has recommended Covaxin for emergency use authorisation; the recommendation, along with rollout modalities, will now be taken up by the DCGI for a final decision on the matter

Covishield DCGI approval: Pune-based Serum Institute will have to provide safety, efficacy and immunogenicity data from the ongoing clinical trials in India and globally

Coronavirus vaccination drive: The task force has added 31 COVID-19 vaccine hubs that will supply vaccines to 29,000 vaccination points

Covishield has become the first coronavirus vaccine to receive a regulatory nod in India. Now, Drug Controller General of India (DCGI) will take a final call on rolling out the inoculation

CDSCO's expert panel has recommended the Serum Institute of India's Covishield COVID-19 vaccine for emergency use authorisation to DCGI